Skip To Main Content
Dan Samorodnitsky on Muck Rack

Dan Samorodnitsky

Verified
Minneapolis
As seen in: BioSpace, National Institutes of Health, Scribd, The Atlantic, WIRED Magazine, New Scientist, The Daily Beast, United States Department of Agriculture (USDA), VICE, VICE UK, Salon and
Covers:  Science, Biology, Genetic Engineering, Climate Change
i'm a science writer. i write about biology, genetics, the environment, stuff like that. my pronouns are he/him. cofounder @sequencermag

Get in touch with Dan

Contact Dan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

When the Central Dogma bends, will it break?

|
By Dan Samorodnitsky Verified
| Sequencer Verified
dan June 24, 2026 6 minute read When the Central Dogma bends, will it break? The discovery of a protein that seemingly contradicts a fundamental law of biology raises a question: how important are those laws anyway?
Open in Who Shared Issue with article?

Disc’s FDA Rejection Raises Questions About Commissioner’s Vouchers

|
By Dan Samorodnitsky Verified
| BioSpace Verified
The FDA’s rejection of Disc Medicine’s rare disease drug bitopertin came as a surprise to the entire biopharma world—including, perhaps, other holders of a coveted Commissioner’s National Priority Voucher. Not only did the rejection take four months to materialize—twice as long as the 1–2 month estimate—but it was based on information known when the voucher was awarded.
Open in Who Shared Issue with article?

Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders

|
By Heather McKenzie Verified, Jef Akst Verified, Dan Samorodnitsky Verified
| BioSpace Verified
> Listen on Spotify > Listen on Apple Products > Listen on Amazon Music > Listen on iHeart Last week, the FDA declined to review Moderna’s mRNA-based flu vaccine, with Center for Biologics Evaluation and Research Director Vinay Prasad himself signing the refuse-to-file (RTF) letter. Prasad said Moderna’s comparator group “does not reflect the best-available standard of care,” while Moderna pushed back, saying CBER had previously found a standard-dose flu shot to be an “acceptable” comparator.
Open in Who Shared Issue with article?
See all 471 licensed articles (475 Total)